Nature:新冠康复者血浆中抗体浓度太低?

2020-06-21 MedSci原创 MedSci原创

从COVID-19康复者身上获得的大多数血浆不含有高水平的中和活性。

COVID-19大流行期间,SARS-CoV-2感染了数百万人,夺去了数十万人的生命。

病毒进入细胞取决于SARS-CoV-2刺突蛋白(S)的受体结合域(RBD)。虽然现今还没有可及的疫苗,但抗体很可能是保护人体的关键。然而,至今为止,我们对SARS-CoV-2的人类抗体反应知之甚少。

最近,研究人员为此探究了149名COVID-19的康复者。在症状发生后平均39天收集到的血浆具有不同的半数最大假病毒中和滴度:33%的人小于1:50,79%的人低于1:1000,而只有1%的人显示滴度高于1:5000。

抗体测序显示,不同个体中RBD特异性记忆B细胞的扩大克隆表达了与之密切相关的抗体。尽管血浆滴度较低,但RBD上三个不同表位的抗体中和的半数最大抑制浓度(IC50值)低至个位数纳克/毫升。

因此,从COVID-19康复者身上获得的大多数血浆不含有高水平的中和活性。

然而,在所有被测试的人中都发现了罕见但反复出现的具有强大抗病毒活性的RBD特异性抗体,这表明为引起这种抗体而设计的疫苗可能广泛有效。

 

原始出处:

Davide F. Robbiani et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals, Nature(2020). 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884404, encodeId=89001884404a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 22 08:16:37 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813776, encodeId=62fb813e7630, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:12:15 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544647, encodeId=7c2a154464e9d, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jun 23 07:16:37 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028213, encodeId=6f8e1028213f8, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jun 21 19:16:37 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2021-05-22 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884404, encodeId=89001884404a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 22 08:16:37 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813776, encodeId=62fb813e7630, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:12:15 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544647, encodeId=7c2a154464e9d, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jun 23 07:16:37 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028213, encodeId=6f8e1028213f8, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jun 21 19:16:37 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1884404, encodeId=89001884404a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 22 08:16:37 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813776, encodeId=62fb813e7630, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:12:15 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544647, encodeId=7c2a154464e9d, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jun 23 07:16:37 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028213, encodeId=6f8e1028213f8, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jun 21 19:16:37 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884404, encodeId=89001884404a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 22 08:16:37 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813776, encodeId=62fb813e7630, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:12:15 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544647, encodeId=7c2a154464e9d, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jun 23 07:16:37 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028213, encodeId=6f8e1028213f8, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jun 21 19:16:37 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2020-06-21 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

Nature:广谱的抗HIV中和抗体疗法优于抗HIV反转录的鸡尾酒疗法

广谱的抗HIV的中和抗体疗法不同于传统的抗反转录的鸡尾酒疗法,能够引起长期的CD8 T细胞的免疫机制从而抑制HIV病毒量。

全球**新冠病毒中和抗体LY-CoV555进入I期临床试验,首批患者给药完成

礼来公司已经开始在其AbCellera合作抗体的1期试验中给COVID-19患者配药。该试验的启动,比原定计划提前进行,标志着SARS-CoV-2反应的新阶段的开始,研究对象将接受专为该病毒设计的药物

NATURE:我国多单位合作发表靶向SARS-CoV-2受体结合位点的人类中和抗体

来自中国科学院微生物研究所,中国科学院武汉病毒研究所,首都医科大学,安徽大学的高福,严景华,袁志明,王奇慧及王福生等团队合作,报告了从一名休养期COVID-19患者中分离出2种特异性的人类单克隆抗体。

礼来启动新冠病毒COVID-19抗体药物的全球临床试验

COVID-19抗体将在不适合使用疫苗的人群中进行评价。

Cell Discovery:甲型流感病毒治疗性抗体研究方面取得进展

流感病毒是一种可以发生持续变异和重组,且极易对流感病毒药物产生耐药性的,具有高度频繁变异的病毒。季节性流感病毒,以及不时出现的跨种间传播、可感染人的禽/猪流感病毒给人们造成了严重的健康和生命威胁。近些年,为了应对各种亚型流感的流行、暴发和病毒抗原变异,可中和多型/亚型流感病毒的广谱中和抗体成为研究的焦点。

JAMA:康复患者血浆用于危重新冠肺炎患者治疗

恢复期含有中和抗体血浆输注可改善COVID-19感染的危重急性呼吸窘迫综合征患者的临床症状